Report - LifeSciences BC

Recommendation Eight: To increase thelevel of overall funding transparency,negotiations with pharmacists and communitypharmacy should provide for a new frameworkfor compensation in respect of dispensing andother professional services provided bypharmacists. The framework should addressthose professional services that can beeffectively and efficiently provided bypharmacists and should be linked to transparentaccountability agreements to maintain and,ideally, improve point-of-care services topatients.Recommendation Nine: The PSD shouldadopt a cautious approach to broadenedutilization of tendering processes. The processadopted should mirror tendering processes usedin other areas of Government characterized bya process that is transparent, fair, open andincludes understandable evaluation criteria.Increased tendering should provide forreasonable levels of patient choice, avoid thedeployment of older inferior products and,where possible, arrangements that provide forparticipation of multiple suppliers.BuildingPositive and ProductiveRelationshipsRecommendation Ten: The DeputyMinister of the Ministry of Health shouldcommit to participate in an annual accountabilitysession to hear from patient groups, fromindustry and from other key stakeholdersregarding improved relations and thestrengthening of the common objectives ofpatient care and choice.Improving the Common DrugReview ProcessRecommendation Eleven: Given that BCwas a lead jurisdiction in calling for theimplementation of the CDR, action should betaken to:1.ensure BC's decision-making processesinclude similar timelines to those used bythe CDR and a greater level ofcommitment to openness andtransparency; and2.that any unnecessary overlap between theCDR and BC formulary managementsystem are reduced to the fullest extentpossible.Replacing or Reconstituting theTherapeutics InitiativeRecommendation Twelve: Subject toRecommendation Four, if the TherapeuticsInitiative is maintained, action must be taken inthe following areas:the governance, membership andaccountability standards associated withthe operation of the Therapeutics Initiativewill require substantial improvement;steps must also be taken to renew andrevitalize the panel of experts theTherapeutics Initiative relies upon todischarge its obligations;THE REPORT OF PHARMACEUTICAL POLICY RECOMMENDATIONS FOR THE MINISTRY OF HEALTH 28 APRIL, 2008